QUECTEL-WIRELESS
Quectel Wireless Solutions, a global IoT solutions provider, today announces that, according to a recent milestone report by Finite State, an independent third-party cybersecurity firm, nearly 95% of all Quectel modules shipped to the United States since the beginning of 2022 have industry-leading security scores based on penetration testing and binary analysis by Finite State.
The report highlights a notable enhancement in Quectel's security position, expanding the number of modules tested and with scores across the tested modules improving from an average of 33 to 18, up from an average of 62 to 24 in previous testing. This represents a substantial improvement, as both the initial and revised scores significantly surpass the industry average of 98 with the lowest (best) score of 10. Further, the number of and severity of vulnerabilities Finite State did identify in Quectel products or modules are significantly less than the industry standard and revealed a very limited attack surface. Those issues Finite State did discover have been quickly remedied by Quectel.
This advanced phase of testing leverages Finite State's security technologies and expertise to conduct an exhaustive third-party evaluation of Quectel's modules. The advanced testing encompasses an array of sophisticated security assessments designed to fortify Quectel's modules against the evolving landscape of cyber threats, including binary analysis of numerous Quectel products and both penetration testing and binary analysis of several Quectel cellular modules.
"Entering this next phase of security testing with Finite State underscores our relentless pursuit of the highest security standards for our products," stated Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "Our continued collaboration is a reflection of our commitment to exceed industry security expectations, ensuring our customers benefit from the most secure and reliable communication modules available – tested and verified by one of the most trusted US cyber security firms. We’re thrilled that the latest report from Finite State demonstrates our commitment and progress."
The continued integration of Finite State into Quectel’s transparency and security program reaffirms Quectel’s commitment to pioneering unparalleled security practices in the IoT and telecommunications sectors. Quectel has made a measurable improvement in key areas such as the security health of the code, the sophistication of the vulnerability management process, and the transparency of its software supply chain.
The program is strategically designed with three key goals to address the pressing issues in cybersecurity today:
- Implementing the Finite State Platform into Quectel's DevSecOps procedures, which enhances firmware binary analysis, manages vulnerabilities efficiently, and offers specific recommendations for remediation.
- Developing and sharing Software Bill of Materials (SBOM) and Vulnerability Exploitability Exchange (VEX) documents for each of Quectel's products, which promotes a transparent environment and provides critical insights into the software components of Quectel's devices along with any vulnerabilities they may contain.
- Conducting comprehensive manual penetration tests by Finite State's expert Red Team, which augments automated testing methods and delivers detailed security evaluations for Quectel's product line.
Matt Wyckhouse, CEO of Finite State, commented, "Progressing to this next phase of security testing demonstrates Quectel’s commitment to leading the industry with transparent, rigorous cybersecurity practices. Quectel's willingness to subject their products to such rigorous scrutiny is commendable and sets a new industry standard to further safeguard the IoT ecosystem."
The outcome of this continued engagement is anticipated to enhance the security framework of Quectel's modules and inspire a shift towards more rigorous security standards across the telecommunications industry. Quectel is dedicated to sharing insights and best practices gleaned from this process, contributing to a safer, more secure digital future.
In addition to the activity with Finite State, Quectel is actively pursuing collaboration with multiple standards-setting organizations to enhance and commit to a more rigorous set of security requirements. This initiative aims to achieve key security certifications from both industry and governmental bodies, underlining Quectel's dedication to advancing security standards within the sector.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318703729/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
